Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company focused on T cell engaging (TCE) bispecific antibodies for solid tumors. The CNTX news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how its pipeline and corporate activities evolve over time.
According to recent announcements, Context is advancing three key programs: CTIM-76, a Claudin 6 x CD3 TCE in a Phase 1 dose-escalation trial for CLDN6-positive ovarian, endometrial, and testicular cancers; CT-95, a Mesothelin x CD3 TCE in a Phase 1 study for mesothelin-expressing solid tumors such as pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers; and CT-202, a Nectin-4 x CD3 TCE in preclinical development with pH-dependent activity designed for the tumor microenvironment. News items often highlight clinical enrollment updates, early safety and anti-tumor activity signals, and preclinical data presented at major oncology meetings.
Investors and followers of CNTX can also see updates on quarterly operating and financial results, at-the-market equity program changes, Nasdaq listing compliance notices and resolutions, and organizational developments such as inducement stock option grants and senior leadership appointments. The company regularly reports participation in scientific and investor conferences, including ASCO, AACR, SITC, and healthcare investment forums, which can signal upcoming data disclosures or corporate visibility efforts.
Use this page to review Context Therapeutics’ latest clinical, financial, and corporate news in one place. For those tracking immuno-oncology and T cell engager developments in solid tumors, the CNTX news stream provides a consolidated view of the company’s reported progress and key milestones.
Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The presentation will feature their clinical asset CTIM-76, a Claudin 6 x CD3 bispecific antibody.
The poster, titled 'Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6,' will be presented on Saturday, November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB of the George R. Brown Convention Center in Houston, TX. The authors of the presentation are Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.
BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:
1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and near-term milestones
3. Potential for up to $118.5 million in additional clinical, regulatory, and commercial milestones
4. BioAtla eligible for tiered royalties on net sales
5. Context anticipates IND filing for BA3362 in mid-2026
This agreement allows BioAtla to focus on its lead clinical CAB programs while advancing BA3362 under Context's leadership. Context views Nectin-4 as a priority target for solid tumors and sees BA3362 as a potentially best-in-class asset.
Context Therapeutics (Nasdaq: CNTX), a biopharmaceutical company focused on solid tumor treatments, has appointed Dr. Karen Smith and Dr. Luke Walker to its Board of Directors. Dr. Smith brings over 20 years of experience in drug development and commercialization, having contributed to successful products like Herceptin and Vyxeos. Dr. Walker offers extensive clinical development expertise, particularly in T cell engaging bispecific antibodies.
These appointments aim to support Context's growth and pipeline advancement. Dr. Smith's oncology drug development and regulatory experience, along with Dr. Walker's track record in oncology drug development, are expected to be valuable assets for the company's strategic goals.
Context Therapeutics (Nasdaq: CNTX) reported its Q2 2024 financial results and recent business highlights. Key points include:
- Acquisition of CT-95, a mesothelin x CD3 bispecific antibody
- Appointment of Dr. Claudio Dansky Ullmann as Chief Medical Officer
- Cash and cash equivalents of $101.5 million as of June 30, 2024
- FDA clearance for CTIM-76 IND, with first patient dosing expected in Q3 2024
- Closed a $100 million private placement in May 2024
- Net loss of $2.3 million for Q2 2024, compared to $5.0 million in Q2 2023
- Cash runway expected to fund operations into 2028
Context Therapeutics (Nasdaq: CNTX) has announced key appointments to support the development of its clinical-stage T cell engaging assets for solid tumors. Dr. Claudio Dansky Ullmann joins as Chief Medical Officer, bringing over 30 years of experience in oncology therapeutics development. Karen Andreas, M.S. is appointed as Vice President of Clinical Operations, with almost 20 years of biopharma experience.
These appointments come as Context advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials. The company is granting stock options to Dr. Dansky Ullmann and other new employees as inducement awards, subject to vesting conditions and Nasdaq listing rules.
Context Therapeutics, a biopharmaceutical company specializing in solid tumor treatments, has acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody from Link Immunotherapeutics. This acquisition, announced on July 10, 2024, aligns with Context’s strategy to expand its pipeline of T cell engager assets. CT-95 has already received Investigational New Drug (IND) clearance from the U.S. FDA and is expected to begin Phase 1 trials in Q1 2025. The antibody targets mesothelin, prevalent in cancers like ovarian, lung, and pancreatic. Context plans to use its existing cash reserves to fund the acquisition and initial clinical trials.
Context Therapeutics Inc. reported on the FDA clearance of their IND application for a Phase 1 clinical trial of CTIM-76 and completed a $100 million financing round. They anticipate funding to last until 2028. The company showcased financial results for Q1 2024, emphasizing a decrease in R&D expenses and a net loss of $3.7 million for the quarter.
Context Therapeutics received FDA clearance for its IND application for a Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, focusing on gynecologic and testicular cancers. The Company aims to enroll the first patient by mid-2024.
Context Therapeutics Inc. announced a $100 million private placement with healthcare investors to advance medicines for solid tumors. The financing will extend the cash runway into 2028. The private placement is expected to close on May 6, 2024, and includes the sale of approximately 64.5 million shares of common stock at $1.55 per share.
Summary not available.